Navidea Biopharmaceuticals to Announce Second Quarter 2014 Financial Results on August 6, 2014
- Conference call with investment community to follow at 8:30 a.m. EDT -
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the second quarter 2014, on Wednesday, August 6, 2014 before the market opens. The announcement will be followed by a conference call with the investment community, at 8:30 a.m. EDT.
Investors and the public are invited to access the live audio webcast through the link below. Participants who would like to ask questions during the question and answer session must participate by telephone also. Participants are encouraged to log-in and/or dial-in fifteen minutes before the conference call begins. The webcast replay is expected to be available on our investor website, http://ir.navidea.com, approximately two to four hours after the live event.
| Event: | Navidea Biopharmaceuticals Q2 2014 Financial Results Conference Call | |
| Date/Time: | Wednesday, August 6, 2014 at 8:30 a.m. EDT | |
| Webcast Link: | ||
| Dial-in Number – US: | 1 (866) 638-3013 | |
| Dial in Number – Int’l: | 1 (630) 691-2761 | |
| Participant Passcode: | 37774632 | |
| Replay |
A webcast replay will be available on the Investor Relations section of our website at http://ir.navidea.com for 30 days. |
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is developing multiple precision diagnostic products and platforms including Manocept™, NAV4694, NAV5001, and NAV1800 (RIGScan™), to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Lymphoseek® (technetium TC 99m tilmanocept) Injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Executive
VP & CFO
or
Sharon Correia, 978-655-2686
Associate
Director, Corporate Communications
Source: Navidea Biopharmaceuticals, Inc.
Released July 29, 2014